Antifungal susceptibility of Candida albicans in biofilms

Mycoses

Volumn 55, Issue 3, 2012, Pages 199-204

  Tobudic, Selma ^a   Kratzer, Christina ^a   Lassnigg, Andrea ^a   Presterl, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antifungal resistance; Biofilm; C. albicans

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; POSACONAZOLE; PYRROLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CATHETER INFECTION; CELL GROWTH; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; HUMANS;

CANDIDA ALBICANS; FUNGI;

EID: 84859971384     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02076.x     Document Type: Article

References (41)

1. Samaranayake LP. Oral candidosis: an old disease in new guises. Dent Update 1990; 17: 36-38.
2. van de Veerdonk FL, Kullberg BJ, Netea MG. Pathogenesis of invasive candidiasis. Curr Opin Crit Care 2010; 16: 453-9.
3. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005; 41(Suppl. 6): S389-93.
4. Presterl E, Daxbock F, Graninger W, Willinger B. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 2007; 13: 1072-6.
5. Costerton JW. Overview of microbial biofilms. J Ind Microbiol 1995; 15: 137-40.
6. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol 2002; 56: 187-209.
7. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
8. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
9. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-39.
10. Baillie GS, Douglas LJ. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 1998; 42: 1900-5.
11. Kumamoto CA. Candida biofilms. Curr Opin Microbiol 2002; 5: 608-11.
12. Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol 2006; 55: 999-1008.
13. Baillie GS, Douglas LJ. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol 1999; 310: 644-56.
14. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-40.
15. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 2004; 72: 6023-31.
16. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004; 230: 13-18.
17. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol 2004; 186: 8172-80.
18. LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 2006; 50: 3839-46.
19. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000; 46: 397-403.
20. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-9.
21. Kuhn DM, Balkis M, Chandra J, Mukherjee PK, Ghannoum MA. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 2003; 41: 506-8.
22. Melo AS, Bizerra FC, Freymuller E, Arthington-Skaggs BA, Colombo AL. Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol 2011; 49: 253-62.
23. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-86.
24. Lamfon H, Porter SR, McCullough M, Pratten J. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study. J Antimicrob Chemother 2004; 53: 383-5.
25. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
26. Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 2008; 52: 357-60.
27. Tobudic S, Lassnigg A, Kratzer C, Graninger W, Presterl E. Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases. Mycoses 2010; 53: 208-14.
28. Andriole VT. Current and future antifungal therapy: new targets for antifungal therapy. Int J Antimicrob Agents 2000; 16: 317-21.
29. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995; 39: 2128-31.
30. Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 2006; 194: 710-3.
31. Kucharikova S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. Antimicrob Agents Chemother 2010; 54: 4474-5.
32. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-8.
33. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828-33.
34. van Etten EW, Otte-Lambillion M, van Vianen W, ten Kate MT, Bakker-Woudenberg AJ. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35: 509-19.
35. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
36. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, Lopez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother 2003; 47: 3657-9.
37. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother 2010; 65: 271-4.
38. Uppuluri P, Chaturvedi AK, Lopez-Ribot JL. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia 2009; 168: 101-9.
39. Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effect of fluconazole, amphotericin B and caspofungin against Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother 2011; 55: 3591-3.
40. Bernhardt H, Knoke M, Bernhardt J. Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation. Mycoses 2011; doi:
41. Schinabeck MK, Long LA, Hossain MA et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 2004; 48: 1727-32.